Efgartigimod administered subcutaneously (SC, coformulated with recombinant human hyaluronidase PH20) is approved for adult patients with generalized myasthenia gravis (gMG; US, EU) and chronic inflammatory demyelinating polyneuropathy (CIDP; US). This evidence concerns the gene SPAM1 and chronic inflammatory demyelinating polyradiculoneuropathy.